Recent analyst ratings for SI-BONE (NASDAQ:SIBN) show a mix of bullish to bearish sentiments, with a slight decline in the average 12-month price target to $25.00 from a previous higher average. Analysts from Piper Sandler, Morgan Stanley, Cantor Fitzgerald, and Truist Securities have updated their ratings and price targets, reflecting dynamic market conditions and SI-BONE's performance. The company, a medical device maker, has shown a revenue growth of 21.61% but struggles with a net margin of -28.26% and below-average ROA, despite a strong ROE of -6.4% and a low debt-to-equity ratio.